fashion -WSS

fashion

author：fashion 2025-09-30 14:59:15 - browse：9756

Sarepta - Cambridge -AP — A logo sign outside of the headquarters of Sarepta Therapeutics in Cambridge, Mass. Kristoffer Tripplaar/Sipa via AP

Reviewers at the Food and Drug Administration were leaning toward rejecting a closely watched gene therapy for Duchenne muscular dystrophy made by Sarepta Therapeutics, prompting a top official to intervene earlier this year, according to three people with direct knowledge of the agency deliberations.

Inside the FDA office that oversees gene therapies, some staff had reached a non-binding conclusion that Sarepta’s gene therapy should be rejected, the individuals said, speaking on condition of anonymity. Peter Marks, a top FDA official and vocal advocate for faster gene therapy approvals, stepped in and directed staff to schedule a public hearing on the therapy on May 12.

Sarepta announced the scheduling of the public hearing last month, but the internal deliberations that led to it have not been previously reported.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： Covid’s new normal has set in amid another rise in cases

entertainment

WSS

Transgender sports debate: Physicians say bans are health issue

Susan Tousi leaves Illumina to head cancer liquid biopsy startup

Assistant physicians can help address the primary care shortage

White House Covid adviser calls on docs to combat misinformation

House panel takes first step toward fixing drug shortages

Feng Zhang CRISPR delivery startup lays off quarter of staff

explore

fashion

focus

New air purifier tech could be key to improving indoor air quality

A single drug, study failures leave Anavex with nothing but cash

Supreme Court strikes down use of affirmative action

The biotech scorecard for Q1: 17 stock

As demand for Covid shots wanes, Moderna seeks its next success

Burning questions for the 2024 JPM Healthcare Conference

The cancer drug shortage isn’t new — and neither are the solutions

UCB departs biotech trade group BIO

Malaria cases in Florida and Texas: Here’s what you need to know

Feng Zhang, Grail founder join forces on new gene editing startup

explore

Chronically ill young patients struggle to find fertility info

AdventHealth escalates lawsuit against insurance vendor Multiplan

Why the quest to eradicate polio has stumbled

U.K. sequencing study surfaces new findings about tumor DNA

Morgan Health, with ambitious aims, wants you to know it’s still here

Chronically ill young patients struggle to find fertility info

explore

hotspot

entertainment

knowledge